Citadel Advisors
SGMO

Citadel Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Citadel Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7K Sell
47,200
-178,700
-79% -$71.1K ﹤0.01% 12739
2025
Q4 		$94.9K Sell
225,900
-21,700
-9% -$11.5K ﹤0.01% 11687
2025
Q3 		$167K Buy
247,600
+41,200
+20% +$22.2K ﹤0.01% 11449
2025
Q2 		$112K Sell
206,400
-153,900
-43% -$91.4K ﹤0.01% 11246
2025
Q1 		$236K Sell
360,300
-247,900
-41% -$262K ﹤0.01% 10117
2024
Q4 		$620K Buy
608,200
+206,700
+51% +$378K ﹤0.01% 8072
2024
Q3 		$348K Buy
401,500
+265,300
+195% +$194K ﹤0.01% 9020
2024
Q2 		$48.8K Buy
136,200
+80,600
+145% +$43.5K ﹤0.01% 11788
2024
Q1 		$37.3K Buy
55,600
+4,000
+8% +$2.9K ﹤0.01% 12470
2023
Q4 		$28K Sell
51,600
-47,400
-48% -$21.9K ﹤0.01% 12324
2023
Q3 		$59.4K Buy
99,000
+55,300
+127% +$59.2K ﹤0.01% 11552
2023
Q2 		$56.8K Buy
43,700
+11,100
+34% +$15.2K ﹤0.01% 11655
2023
Q1 		$57.4K Sell
32,600
-26,300
-45% -$75.1K ﹤0.01% 11981
2022
Q4 		$185K Buy
58,900
+11,500
+24% +$44.6K ﹤0.01% 10267
2022
Q3 		$232K Sell
47,400
-13,500
-22% -$69.3K ﹤0.01% 10105
2022
Q2 		$252K Sell
60,900
-33,200
-35% -$144K ﹤0.01% 10207
2022
Q1 		$547K Sell
94,100
-219,200
-70% -$1.3M ﹤0.01% 9168
2021
Q4 		$2.35M Sell
313,300
-11,300
-3% -$98.2K ﹤0.01% 5875
2021
Q3 		$2.92M Sell
324,600
-31,000
-9% -$306K ﹤0.01% 5425
2021
Q2 		$4.26M Sell
355,600
-108,800
-23% -$1.23M ﹤0.01% 4792
2021
Q1 		$5.82M Buy
464,400
+93,600
+25% +$1.26M ﹤0.01% 3931
2020
Q4 		$5.79M Buy
370,800
+153,400
+71% +$1.8M ﹤0.01% 3434
2020
Q3 		$2.05M Sell
217,400
-48,100
-18% -$520K ﹤0.01% 4657
2020
Q2 		$2.38M Buy
265,500
+11,700
+5% +$109K ﹤0.01% 4267
2020
Q1 		$1.62M Buy
253,800
+41,200
+19% +$306K ﹤0.01% 4493
2019
Q4 		$1.78M Buy
212,600
+85,600
+67% +$787K ﹤0.01% 4603
2019
Q3 		$1.15M Sell
127,000
-69,100
-35% -$775K ﹤0.01% 5355
2019
Q2 		$2.11M Sell
196,100
-27,700
-12% -$295K ﹤0.01% 4421
2019
Q1 		$2.13M Sell
223,800
-83,100
-27% -$849K ﹤0.01% 4354
2018
Q4 		$3.52M Sell
306,900
-57,900
-16% -$719K ﹤0.01% 3300
2018
Q3 		$6.18M Buy
364,800
+114,600
+46% +$1.74M ﹤0.01% 2721
2018
Q2 		$3.55M Buy
250,200
+43,200
+21% +$718K ﹤0.01% 3250
2018
Q1 		$3.93M Buy
207,000
+91,300
+79% +$1.95M ﹤0.01% 2752
2017
Q4 		$1.9M Buy
115,700
+74,500
+181% +$1.11M ﹤0.01% 3713
2017
Q3 		$618K Buy
41,200
+5,300
+15% +$58.6K ﹤0.01% 5006
2017
Q2 		$316K Buy
35,900
+2,800
+8% +$18K ﹤0.01% 5814
2017
Q1 		$172K Sell
33,100
-23,200
-41% -$93.1K ﹤0.01% 6624
2016
Q4 		$172K Buy
56,300
+19,900
+55% +$72.5K ﹤0.01% 6410
2016
Q3 		$169K Buy
36,400
+8,800
+32% +$44.8K ﹤0.01% 6409
2016
Q2 		$160K Buy
27,600
+5,700
+26% +$36.3K ﹤0.01% 5984
2016
Q1 		$132K Sell
21,900
-9,100
-29% -$54.6K ﹤0.01% 5898
2015
Q4 		$283K Sell
31,000
-4,700
-13% -$36.2K ﹤0.01% 5296
2015
Q3 		$201K Buy
35,700
+12,700
+55% +$105K ﹤0.01% 6148
2015
Q2 		$255K Buy
23,000
+8,400
+58% +$108K ﹤0.01% 5988
2015
Q1 		$229K Sell
14,600
-21,700
-60% -$336K ﹤0.01% 6017
2014
Q4 		$552K Buy
36,300
+2,000
+6% +$24.3K ﹤0.01% 4598
2014
Q3 		$370K Buy
34,300
+4,300
+14% +$56.2K ﹤0.01% 5015
2014
Q2 		$458K Sell
30,000
-17,100
-36% -$246K ﹤0.01% 4509
2014
Q1 		$852K Sell
47,100
-5,100
-10% -$98.3K ﹤0.01% 3639
2013
Q4 		$725K Buy
52,200
+21,800
+72% +$251K ﹤0.01% 3565
2013
Q3 		$319K Buy
30,400
+13,300
+78% +$132K ﹤0.01% 4279
2013
Q2 		$134K Buy
+17,100
New +$149K ﹤0.01% 4997

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's SGMO Position: Q4 2025 in Review

Citadel Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 1,208,415 shares — an estimated $641K sold.

Citadel Advisors first reported a position in SGMO in Q2 2013 and held it in 48 quarters. The position peaked at $20.5M in Q2 2019. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Citadel Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,208,415 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $641K.
  • Citadel Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 48 quarters.
  • Citadel Advisors's SANGAMO THERAPEUTICS INC position peaked at $20.5M in Q2 2019.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.